Pulmatrix and Cipla Technologies announce commercialization agreement for Pulmazole™
Pulmatrix and Cipla Technologies announced a Definitive Agreement for co-development and commercialization of Pulmazole™ (PUR1900) – an inhaled iSPERSE™ formulation of the anti-fungal drug itraconazole for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in patients with asthma. April 15, 2019